Literature DB >> 1926844

Autocrine growth factors and solid tumor malignancy.

J H Walsh1, W E Karnes, F Cuttitta, A Walker.   

Abstract

The ability of malignant cells to escape the constraint that normally regulate cell growth and differentiation has been a primary focus of attention for investigators of cancer cell biology. An outcome of this attention has been the discovery that the protein products of oncogenes play a role in the activation of growth signal pathways. A second outcome, possibly related to abnormal oncogene expression, has been the discovery that malignant cells frequently show an ability to regulate their own growth by the release of autocrine growth modulatory substances. Most important, the growth of certain malignant cell types has been shown to depend on autocrine growth circuits. A malignant tumor whose continued growth depends on the release of an autocrine growth factor may be vulnerable to treatment with specific receptor antagonists or immunoneutralizing antibodies designed to break the autocrine circuit. Information is rapidly emerging concerning autocrine growth factors in selected human solid tissue malignancy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1926844      PMCID: PMC1002946     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  176 in total

1.  Production of an insulin-like growth factor by osteosarcoma.

Authors:  J Blatt; C White; S Dienes; H Friedman; T P Foley
Journal:  Biochem Biophys Res Commun       Date:  1984-08-30       Impact factor: 3.575

2.  Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture.

Authors:  R W Furlanetto; J N DiCarlo
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

3.  Localization of insulin-like growth factor genes to human chromosomes 11 and 12.

Authors:  J V Tricoli; L B Rall; J Scott; G I Bell; T B Shows
Journal:  Nature       Date:  1984 Aug 30-Sep 5       Impact factor: 49.962

4.  Sequence of a cDNA clone encoding human preproinsulin-like growth factor II.

Authors:  G I Bell; J P Merryweather; R Sanchez-Pescador; M M Stempien; L Priestley; J Scott; L B Rall
Journal:  Nature       Date:  1984 Aug 30-Sep 5       Impact factor: 49.962

5.  Insulin-like growth factor II precursor gene organization in relation to insulin gene family.

Authors:  T J Dull; A Gray; J S Hayflick; A Ullrich
Journal:  Nature       Date:  1984 Aug 30-Sep 5       Impact factor: 49.962

6.  Mammotroph autoregulation: uptake of secreted prolactin and inhibition of secretion.

Authors:  J Kadowaki; N Ku; W S Oetting; A M Walker
Journal:  Endocrinology       Date:  1984-06       Impact factor: 4.736

7.  Expression of the normal human sis/PDGF-2 coding sequence induces cellular transformation.

Authors:  A Gazit; H Igarashi; I M Chiu; A Srinivasan; A Yaniv; S R Tronick; K C Robbins; S A Aaronson
Journal:  Cell       Date:  1984-11       Impact factor: 41.582

8.  Bombesin and the C-terminal tetradecapeptide of gastrin-releasing peptide are growth factors for normal human bronchial epithelial cells.

Authors:  J C Willey; J F Lechner; C C Harris
Journal:  Exp Cell Res       Date:  1984-07       Impact factor: 3.905

9.  Presence of transforming growth factors in human breast cancer cells.

Authors:  D S Salomon; J A Zwiebel; M Bano; I Losonczy; P Fehnel; W R Kidwell
Journal:  Cancer Res       Date:  1984-09       Impact factor: 12.701

10.  Bombesin-like peptides and receptors in human tumor cell lines.

Authors:  T W Moody; V Bertness; D N Carney
Journal:  Peptides       Date:  1983 Sep-Oct       Impact factor: 3.750

View more
  8 in total

1.  Understanding autocrine growth regulation.

Authors:  R J Coffey; J A Barnard
Journal:  West J Med       Date:  1991-08

2.  Oncogenic Signalling of Growth Factor Receptors in Cancer: Mechanisms and Therapeutic Opportunities.

Authors:  Anica Dricu
Journal:  Int J Mol Sci       Date:  2022-07-02       Impact factor: 6.208

3.  Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.

Authors:  Yuyu He; Jie Li; Tomoyuki Koga; Jun Ma; Sanjay Dhawan; Yuta Suzuki; Frank Furnari; Varun V Prabhu; Joshua E Allen; Clark C Chen
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

Review 4.  Pumping the brakes on RAS - negative regulators and death effectors of RAS.

Authors:  Desmond R Harrell Stewart; Geoffrey J Clark
Journal:  J Cell Sci       Date:  2020-02-10       Impact factor: 5.285

Review 5.  Combination therapy in combating cancer.

Authors:  Reza Bayat Mokhtari; Tina S Homayouni; Narges Baluch; Evgeniya Morgatskaya; Sushil Kumar; Bikul Das; Herman Yeger
Journal:  Oncotarget       Date:  2017-06-06

6.  Magnolin targeting of ERK1/2 inhibits cell proliferation and colony growth by induction of cellular senescence in ovarian cancer cells.

Authors:  Ji-Hong Song; Cheol-Jung Lee; Hyun-Jung An; Sun-Mi Yoo; Han C Kang; Joo Y Lee; Kwang D Kim; Dae J Kim; Hye S Lee; Yong-Yeon Cho
Journal:  Mol Carcinog       Date:  2018-09-21       Impact factor: 4.784

Review 7.  Mechanisms of receptor tyrosine kinase activation in cancer.

Authors:  Zhenfang Du; Christine M Lovly
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

8.  Time scales and wave formation in non-linear spatial public goods games.

Authors:  Gregory J Kimmel; Philip Gerlee; Philipp M Altrock
Journal:  PLoS Comput Biol       Date:  2019-09-23       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.